OneStream, Inc.(OS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OS OneStream, Inc.

Market Closed 12-12 16:00:00 EST

17.74

-0.32

-1.77%

盘后17.87

+0.13+0.73%

18:51 EST

High18.18	Low17.51	Vol906.33K
Open18.07	D1 Closing18.06	Amplitude3.71%
Mkt Cap4.35B	Tradable Cap3.92B	Total Shares244.98M
T/O16.11M	T/O Rate0.41%	Tradable Shares220.70M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OS","market":"US","secType":"STK","nameCN":"OneStream, Inc.","latestPrice":17.74,"timestamp":1765573200000,"preClose":18.06,"halted":0,"volume":906326,"hourTrading":{"tag":"盘后","latestPrice":17.87,"preClose":17.74,"latestTime":"18:51 EST","volume":17224,"amount":305657.04,"timestamp":1765583490774},"delay":0,"floatShares":220698554,"shares":244977000,"eps":-0.97803,"marketStatus":"Market Closed","change":-0.32,"latestTime":"12-12 16:00:00 EST","open":18.065,"high":18.18,"low":17.51,"amount":16108886.061231999,"amplitude":0.037099,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.97803,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1721793600000,"exchange":"NASDAQ","adjPreClose":18.06,"preHourTrading":{"tag":"盘前","latestPrice":18.1491,"preClose":18.06,"latestTime":"09:24 EST","volume":179,"amount":3264.413692,"timestamp":1765549466487},"postHourTrading":{"tag":"盘后","latestPrice":17.87,"preClose":17.74,"latestTime":"18:51 EST","volume":17224,"amount":305657.04,"timestamp":1765583490774},"volumeRatio":0.6026289934675048,"impliedVol":0.5805,"impliedVolPercentile":0.392},"requestUrl":"/m/hq/s/OS/wiki","defaultTab":"wiki","newsList":[{"id":"2591685761","title":"Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2591685761","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591685761?lang=en_us&edition=fundamental","pubTime":"2025-12-13 02:35","pubTimestamp":1765564500,"startTime":"0","endTime":"0","summary":"Arcus ends its Phase 3 STAR-221 trial after a futility review and shifts R&D toward casdatifan, supported by strong early RCC data and key 2026 milestones.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/12/Medical-Development-Laboratory-Caucasian.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/12/Medical-Development-Laboratory-Caucasian.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49370717/arcus-revamps-cancer-pipeline-following-trial-miss-prioritizes-kidney-drug","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49370717/arcus-revamps-cancer-pipeline-following-trial-miss-prioritizes-kidney-drug","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4585","OS","LU2087621335.USD","LU1430594728.SGD","BK4568","BK4578","IE00BSNM7G36.USD","IE00B19Z3581.USD","BK4588","BK4139","LU1066051498.USD","IE00BZ1G4Q59.USD","IE00B7SZLL34.SGD","GILD","IE0002270589.USD","LU2324357040.USD","LU0109394709.USD","LU0289739699.SGD","LU1585245621.USD","LU1839511570.USD","LU2089984988.USD","LU0889565916.HKD","SG9999015978.USD","BK4550","BK4532","LU0114720955.EUR","LU1674673691.USD","LU0234570918.USD","LU1778281490.HKD","BK4097","BK4566","LU0058720904.USD","LU1066053197.SGD","IE00BKVL7J92.USD","LU1674673428.USD","LU0320765992.SGD","LU2468319806.SGD","SG9999015945.SGD","LU0882574055.USD","LU1571399168.USD","BK4583","SG9999015986.USD","IE00B19Z3B42.SGD","RCUS","LU0823416689.USD","SG9999015952.SGD","IE00B3T34201.USD"],"gpt_icon":0},{"id":"2590154331","title":"Roche's Oral Breast Cancer Drug Shows 30% Drop In Recurrence In Patients With Early Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2590154331","media":"Benzinga_recent_news","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590154331?lang=en_us&edition=fundamental","pubTime":"2025-12-12 01:27","pubTimestamp":1765474020,"startTime":"0","endTime":"0","summary":"Roche's giredestrant cut recurrence risk by 30% in the phase 3 lidERA study, showing strong benefits in early ER-positive breast cancer with a consistent safety profile.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/11/Roche-Logo--Signage-On-The-Facade-Of-Roc.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/11/Roche-Logo--Signage-On-The-Facade-Of-Roc.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49341601/roches-oral-breast-cancer-drug-shows-30-drop-in-recurrence-in-patients-with-early-disease","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49341601/roches-oral-breast-cancer-drug-shows-30-drop-in-recurrence-in-patients-with-early-disease","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU0320765489.SGD","BK4532","LU0211331839.USD","BK4097","IE00BFTCPJ56.SGD","OS","LU0208291251.USD","BK4007","BK4585","IE00BJT1NW94.SGD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","IE0002141913.USD","BK4588","BK4578","LU0070302665.USD","IE0009355771.USD","NVS"],"gpt_icon":0},{"id":"2590597165","title":"InnoCare Announces Approval of the Next-Generation TRK Inhibitor Zurletrectinib in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2590597165","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590597165?lang=en_us&edition=fundamental","pubTime":"2025-12-11 19:03","pubTimestamp":1765450980,"startTime":"0","endTime":"0","summary":"BEIJING, Dec.  11, 2025  (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company, announced today that its next-generation TRK inhibitor, zurletrectinib (IC","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3203741/0/en/InnoCare-Announces-Approval-of-the-Next-Generation-TRK-Inhibitor-Zurletrectinib-in-China.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","NGS","BK4097","ORR","BK4195","PFS","BK4179","OS"],"gpt_icon":0},{"id":"2590558532","title":"Is OneStream’s 41.6% Slide in 2025 Creating a Long Term Opportunity?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590558532","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590558532?lang=en_us&edition=fundamental","pubTime":"2025-12-10 13:24","pubTimestamp":1765344249,"startTime":"0","endTime":"0","summary":"If you are wondering whether OneStream at $18.38 is a bargain or a value trap, you are not alone. This breakdown is intended to help you evaluate it with more confidence.\nThe stock is down 0.9% over the last week, 22.6% over the past month, and 35.0% year to date, extending a tough 41.6% slide over the past year that has reset expectations and risk perceptions.\nRecently, investors have been digesting a wave of commentary around high growth software names, with shifting sentiment on how much...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/8042000-choice1-main-header/1585186669041","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8042000-choice1-main-header/1585186669041"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/software/nasdaq-os/onestream/news/is-onestreams-416-slide-in-2025-creating-a-long-term-opportu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/software/nasdaq-os/onestream/news/is-onestreams-416-slide-in-2025-creating-a-long-term-opportu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4097","DCF","OS"],"gpt_icon":0},{"id":"2590346407","title":"BriaCell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout","url":"https://stock-news.laohu8.com/highlight/detail?id=2590346407","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590346407?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:30","pubTimestamp":1765283400,"startTime":"0","endTime":"0","summary":"Over 230 patients screened and over 160 patients enrolled in BriaCell’s pivotal Phase 3 study in metastatic breast cancer (MBC)Enrollment exceeding expectations with strong clinical site and patient i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202256/0/en/BriaCell-s-Phase-3-Patient-Enrollment-on-Track-for-1H2026-Topline-Data-Readout.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBC","BK4139","BK4097","OS","BK4086","CPI","BCTX"],"gpt_icon":0},{"id":"2590456673","title":"1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years","url":"https://stock-news.laohu8.com/highlight/detail?id=2590456673","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590456673?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:15","pubTimestamp":1765282500,"startTime":"0","endTime":"0","summary":"Progression-free response stayed consistent across age, BMI, and menopausal status in MONALEESA pooled analysis1 KISQALI is only CDK4/6i to demonstrate statistically significant overall survival (OS) ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202238/0/en/1-in-4-metastatic-breast-cancer-patients-treated-with-Novartis-Kisqali-remain-progression-free-beyond-4-years.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EBC","IE00BN0W2W23.USD","BK4590","LU1543694498.USD","LU2092937221.SGD","BK4211","BK4561","OS","BK4097","A","IE00BN0W2T93.GBP","BK4588","FUL","LU2229751404.USD","BK4581","BK4567","DDFS","PFS","LU2089279066.USD","BK4195","LU2041044095.USD","LU0347712357.USD","LU1165135440.EUR","BK4109","LU1721428933.USD","ET","LU2413666699.HKD","BK4585","LU2413666426.HKD","BK4144","IE00BN0W2V16.EUR","BK4121"],"gpt_icon":0},{"id":"2590318860","title":"Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+ in patients with first line advanced melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2590318860","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590318860?lang=en_us&edition=fundamental","pubTime":"2025-12-09 15:00","pubTimestamp":1765263600,"startTime":"0","endTime":"0","summary":"Progression free survival (PFS) of 74% at 16 months compares favourably to standard of care PFS of 50% at 11.5 months1 Strong PFS consistent across key subgroups Reaffirms selection of iSCIB1+ and tar","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202069/0/en/Scancell-updated-Phase-2-data-shows-continued-improvement-in-progression-free-survival-with-iSCIB1-in-patients-with-first-line-advanced-melanoma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","BK4097","BK4142","IE00B1G9WX41.USD","BK4211","MAR","BK4156","IE00B0T0GQ85.USD","BK4588","LU0690374961.EUR","GB00B4LPDJ14.GBP","IE00B95QR487.USD","IE00BD0PCF45.HKD","LU1718418525.SGD","LU0690374615.EUR","IE00B45NX917.SGD","OS","LU2404859741.USD","LU2404859667.USD","GB00B4QBRK32.GBP","PFS","BK4585"],"gpt_icon":0},{"id":"2590910366","title":"Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2590910366","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590910366?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:30","pubTimestamp":1765229400,"startTime":"0","endTime":"0","summary":"Media ReleaseCOPENHAGEN, Denmark; December 8, 2025 Two-year epcoritamab monotherapy data demonstrate high complete response and encouraging survival rates in patients with Richter transformation (RT),","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201984/0/en/Genmab-Announces-New-Data-from-Phase-1b-2-EPCORE-CLL-1-Highlighting-Potential-of-Epcoritamab-as-Monotherapy-and-in-Combination-for-Patients-with-Richter-Transformation-RT.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4187","BK4211","BK4109","BK4195","CR","ASH","ORR","LU2463526074.USD","OS","BK4097","IE00B19Z4B17.USD","IE0031619046.USD","CRS","LU2065731478.USD","LU0963586101.USD","BK4006","IE00B66KJ199.SGD","PFS","BK4161","IE00B7SZL793.SGD"],"gpt_icon":0},{"id":"2590368866","title":"Why Is Arcellx Stock Surging Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590368866","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590368866?lang=en_us&edition=fundamental","pubTime":"2025-12-09 02:23","pubTimestamp":1765218180,"startTime":"0","endTime":"0","summary":"Arcellx shares updated ASH data showing strong response and survival results for anito-cel in relapsed multiple myeloma, with analysts highlighting its emerging profile.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/08/Tumor-Microenvironment-Concept-With-Canc.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/08/Tumor-Microenvironment-Concept-With-Canc.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49265004/why-is-arcellx-stock-surging-today","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49265004/why-is-arcellx-stock-surging-today","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["SG9999015952.SGD","LU1066053197.SGD","LU1674673428.USD","BK4097","BK4566","BK4109","LU0234570918.USD","LU0320765992.SGD","LU0889565916.HKD","BK4139","BK4550","BK4578","OS","BK4585","LU2087621335.USD","LU2089984988.USD","GILD","LU0114720955.EUR","IE00B7SZLL34.SGD","PFS","SG9999015986.USD","LU2324357040.USD","IE00BSNM7G36.USD","LU1571399168.USD","LU1778281490.HKD","LU1839511570.USD","SG9999015978.USD","ACLX","LU0289739699.SGD","BK4532","LU1430594728.SGD","LU2463526074.USD","BK4211","SG9999015945.SGD","ASH","LU0058720904.USD","LU1585245621.USD","LU0109394709.USD","LU0823416689.USD","IE00B3T34201.USD","IE00B19Z3B42.SGD","BK4195","BK4588","BK4583","LU0882574055.USD","ORR","LU1674673691.USD","IE0002270589.USD","IE00B19Z3581.USD","LU1066051498.USD"],"gpt_icon":0},{"id":"2589354927","title":"Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2589354927","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589354927?lang=en_us&edition=fundamental","pubTime":"2025-12-08 23:30","pubTimestamp":1765207800,"startTime":"0","endTime":"0","summary":"Patients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably to results with other therapies Data supports ongoing r","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201702/0/en/Corvus-Pharmaceuticals-Presents-Final-Data-from-Soquelitinib-Phase-1-1b-T-Cell-Lymphoma-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","CRVS","ASH","BK4097","BK4211","OS","BK4139","BK4109","LU2463526074.USD","BK4195","BK4568"],"gpt_icon":0},{"id":"2589355106","title":"Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2589355106","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589355106?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:35","pubTimestamp":1765200900,"startTime":"0","endTime":"0","summary":"Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of high-grade cytokine release syndrome (CRS) and immune e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201559/0/en/Autolus-Therapeutics-Presents-Initial-Clinical-Data-in-Pediatric-r-r-B-ALL-Patients-and-Other-Oncology-Data-at-the-American-Society-of-Hematology-ASH-Annual-Meeting-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4117","IE00B66KJ199.SGD","BK4107","BK4585","BK4007","IE0031619046.USD","OS","UCL","BK4132","CRS","FC","BK4097","BK4533","CR","LU0963586101.USD","BK4187","BK4123","BK4109","BK4161","AFG","BK4022","IE00B7SZL793.SGD","BK4539","ALL","ASH","LENZ","BK4006","BK4230","LU1699723380.USD","LU2463526074.USD","LU0985320562.USD","IE00B19Z4B17.USD","LU1571399168.USD","BK4139","BK4588","LU2355687059.USD","CAR","ORR","LU2065731478.USD"],"gpt_icon":0},{"id":"2589533799","title":"Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum","url":"https://stock-news.laohu8.com/highlight/detail?id=2589533799","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589533799?lang=en_us&edition=fundamental","pubTime":"2025-12-08 19:50","pubTimestamp":1765194600,"startTime":"0","endTime":"0","summary":"– First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability among primarily R/R NPM1m, KMT2Ar, and NUP98r acute le","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201378/0/en/Syndax-Highlights-Leadership-in-Menin-Inhibition-at-ASH-2025-with-Multiple-Revuforj-revumenib-Presentations-Spanning-the-Acute-Leukemia-Treatment-Continuum.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0985320562.USD","LU1699723380.USD","LU2355687059.USD","ORR","BK4533","OS","LU1571399168.USD","BK4107","ASH","LU2463526074.USD","CR","BK4585","ALL","BK4109","BK4097","BK4161","BK4129","BK4588","ECG","HSCT"],"gpt_icon":0},{"id":"2589807890","title":"ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances","url":"https://stock-news.laohu8.com/highlight/detail?id=2589807890","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589807890?lang=en_us&edition=fundamental","pubTime":"2025-12-08 09:10","pubTimestamp":1765156200,"startTime":"0","endTime":"0","summary":"Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall response rate(ORR) in this subgroup of patients80% ORR achieved in newly diag","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201167/0/en/ASH-2025-Ascentage-Pharma-Presents-Encouraging-Data-from-Phase-Ib-II-Study-of-Bcl-2-Inhibitor-Lisaftoclax-in-Venetoclax-Exposed-Patients-with-Myeloid-Malignances.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4203","ORR","AAPG","HR","ASH","BK4097","OS","BK4139","BK4109","LU2463526074.USD","BK4225"],"gpt_icon":0},{"id":"2589802971","title":"RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study","url":"https://stock-news.laohu8.com/highlight/detail?id=2589802971","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589802971?lang=en_us&edition=fundamental","pubTime":"2025-12-08 09:00","pubTimestamp":1765155600,"startTime":"0","endTime":"0","summary":"SINGAPORE, Dec. 8, 2025 First and only chemotherapy-free combination in the first-line setting to demonstrate an overall survival benefit versus osimertinibamong Asian patients.Results from 501 participants who self-identified as Asian in the MARIPOSA trial, showed those treated with amivantamab plus lazertinib had a 26 percent lower risk of death compared with osimertinib , based on a median follow-up of 38.7 months. MedianOSfor the combination was not yet reached compared with 38.4months for osimertinib . Survival projections suggest that amivantamab plus lazertinib could extend median OS to more than a year beyond that achieved with osimertinib. At three years, 61 percent of patients treated with the combination were alive compared with 53 percent of those receiving osimertinib. The survival advantage was maintained at 42 months, with survival rates of 59 percent and 46 percent,respec","market":"nz","thumbnail":"https://mma.prnewswire.com/media/2771572/1298d71d_502d_4bb1_9019_512d4a14e9a7_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2771572/1298d71d_502d_4bb1_9019_512d4a14e9a7_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-delivers-statistically-significant-and-clinically-meaningful-improvement-in-overall-survival-benefit-for-asian-patients-with-egfr-mutated-non-small-cell-lung-cancer-in-the--302633939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2592432038.USD","IE00B1BXHZ80.USD","LU0912757837.SGD","LU2089984988.USD","LU0098860793.USD","IE00BJT1NW94.SGD","LU0234572021.USD","IE00B19Z3B42.SGD","IE00B3T34201.USD","LU2505996509.AUD","LU0345770993.USD","SEER","IE00B4R5TH58.HKD","ORR","LU1162221912.USD","LU1267930813.SGD","BK4581","BK4195","BK4585","PFS","BK4504","LU1732799900.SGD","IE00BLSP4452.SGD","LU2505996681.GBP","BK4550","IE00B19Z3581.USD","LU0345770308.USD","LU1778281490.HKD","LU2602419157.SGD","LU1929549753.HKD","BK4559","IE00B3PB1722.GBP","IE00BGHQF631.EUR","LU2468319806.SGD","OS","JNJ","LU0203347892.USD","LU0345769631.USD","ORR.AU","LU1066051225.USD","LU1074936037.SGD","LU0058720904.USD","BK4534","LU2129689431.USD","LU1894683348.USD","LU1261432733.SGD","LU1674673691.USD","LU0466842654.USD","LU2129689514.USD","BK7095"],"gpt_icon":0},{"id":"2589877324","title":"ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2589877324","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589877324?lang=en_us&edition=fundamental","pubTime":"2025-12-07 21:00","pubTimestamp":1765112400,"startTime":"0","endTime":"0","summary":"- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL) comparing favorably to an appr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/07/3201128/0/en/ALX-Oncology-Announces-Positive-Results-from-Ongoing-Investigator-Sponsored-Phase-2-Trial-Evaluating-Evorpacept-in-Combination-with-Standard-of-Care-Treatment-in-Patients-with-Indo.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","SMP","BK4213","ALX","BK4124","PFS","BK4211","OS","BK4080","BK4097","BK4195","BK4231","LU2463526074.USD","ORR","CR","ASH","PR","BK4109"],"gpt_icon":0},{"id":"2589782202","title":"TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition","url":"https://stock-news.laohu8.com/highlight/detail?id=2589782202","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589782202?lang=en_us&edition=fundamental","pubTime":"2025-12-07 06:30","pubTimestamp":1765060200,"startTime":"0","endTime":"0","summary":"Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52) 3/3 (100%) of TSC-101-treated patients who reached two-year follow-up re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/06/3201100/0/en/TScan-Therapeutics-Announces-Positive-Updated-Data-from-the-ALLOHA-Phase-1-Heme-Trial-at-the-67th-American-Society-of-Hematology-Annual-Meeting-and-Exposition.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS","AFG","BK4139","BK4539","BK4117","BK4107","KOL","BK4097","ASH","BK4007","LENZ","LU2463526074.USD","BK4109"],"gpt_icon":0},{"id":"2589800824","title":"OneStream (OS): Assessing Valuation After Strategic Leadership Changes and AI-Focused Growth Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2589800824","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589800824?lang=en_us&edition=fundamental","pubTime":"2025-12-07 01:21","pubTimestamp":1765041689,"startTime":"0","endTime":"0","summary":"OneStream (OS) just reshuffled its C suite, elevating AI leader Scott Leshinski to president, promoting Pamela McIntyre to chief accounting officer, and outlining a CFO handoff to board veteran John Kinzer.\nSee our latest analysis for OneStream.\nThe leadership reshuffle comes after a tough stretch in the market, with a year to date share price return of minus 35.03 percent and a one year total shareholder return of minus 40.18 percent, suggesting sentiment has cooled even as management leans...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/8042000-choice1-main-header/1585186669041","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8042000-choice1-main-header/1585186669041"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/software/nasdaq-os/onestream/news/onestream-os-assessing-valuation-after-strategic-leadership","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/software/nasdaq-os/onestream/news/onestream-os-assessing-valuation-after-strategic-leadership","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4587","AI","BK4023","BK4528","BK4097","OS","BK4585","BK4551","BK4543","BK4588"],"gpt_icon":0},{"id":"2589261588","title":"Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2589261588","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589261588?lang=en_us&edition=fundamental","pubTime":"2025-12-06 22:30","pubTimestamp":1765031400,"startTime":"0","endTime":"0","summary":"Media ReleaseCOPENHAGEN, Denmark; December 6, 2025 New two- and three-year EPCORE NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in pat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/06/3201065/0/en/Genmab-Announces-Data-From-Multiple-Clinical-Trials-Showing-Treatment-with-Fixed-Duration-Epcoritamab-Led-to-Remissions-in-First-Line-Diffuse-Large-B-Cell-Lymphoma-DLBCL-and-Follic.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4226","BK4187","IPI","IE00B7SZL793.SGD","BR","BK4585","BK4588","IE00B66KJ199.SGD","LU0390134368.USD","CR","LU0963586101.USD","LU0545562505.USD","CRS","ASH","LU2463526074.USD","OS","BK4106","BK4161","BK4109","LU1228905037.USD","IE0009354923.USD","BK4211","LU1228905540.USD","IE0034235188.USD","BK4548","BK4006","LU2065731478.USD","BK4097","BK4195","ORR","PFS","BK4093","IE0031619046.USD","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2589841767","title":"Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2589841767","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589841767?lang=en_us&edition=fundamental","pubTime":"2025-12-06 11:11","pubTimestamp":1764990660,"startTime":"0","endTime":"0","summary":"Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment for R/M NPC, achieving mO","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/06/3201030/0/en/Toripalimab-Presents-Long-Term-Survival-Benefits-as-1st-line-Treatment-for-Advanced-Nasopharyngeal-Carcinoma-and-Esophageal-Squamous-Cell-Carcinoma-Patients.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","BK4161","BK4157","PFS","LU0053671581.USD","IE0031619046.USD","IE00B66KJ199.SGD","IE00B7SZL793.SGD","BK4195","OS","LU1815336091.USD","LU0054578231.USD","BK4211","GP","ORR","AEIS","IE00B19Z4B17.USD","LU0757428866.USD","ITT","HCC","RCC","BK4149","BK4097"],"gpt_icon":0},{"id":"2589550638","title":"Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA","url":"https://stock-news.laohu8.com/highlight/detail?id=2589550638","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589550638?lang=en_us&edition=fundamental","pubTime":"2025-12-05 08:00","pubTimestamp":1764892800,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, Dec.  04, 2025  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International(NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company e","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/05/3200415/0/en/Ascentage-Pharma-Announces-Global-Registrational-Phase-III-Study-of-Olverembatinib-in-First-Line-Treatment-of-Ph-ALL-Cleared-by-US-FDA-and-EMA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4134","IE00BDGV0183.EUR","LU0348723411.USD","LU0792757196.USD","LU1880398471.USD","LU2286300806.USD","LU1571399168.USD","LU1066051225.USD","LU1894683348.USD","LU2506952097.USD","CSCO","AAPG","LU0868494617.USD","LU1674673428.USD","IE00B3PB1722.GBP","OS","LU1244550577.SGD","IE00BFMHRM44.USD","LU0985320562.USD","ASH","BK4017","LU1778281490.HKD","LU2237443382.USD","CR","LU1221951046.USD","LU1929549753.HKD","LU1221951129.SGD","BK4581","LU1244550221.USD","IE00BZ1G4Q59.USD","BK4560","IE00BVYPNW00.USD","III","BK4020","BK4579","BK4161","SG9999015986.USD","LU0234572021.USD","ALL","BK4139","CDE","BK4525","EMA","LU0868494708.USD","LU1599440770.SGD","BK4585","IE00BFXG1179.USD","LU0234570918.USD","LU0203347892.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.onestream.com","stockEarnings":[{"period":"1week","weight":-0.0338},{"period":"1month","weight":-0.1984},{"period":"3month","weight":-0.0648},{"period":"6month","weight":-0.3551},{"period":"1year","weight":-0.427},{"period":"ytd","weight":-0.378}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"OneStream, Inc.","nameEN":"OneStream, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"OneStream, Inc.(OS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest OneStream, Inc.(OS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"OneStream, Inc.,OS,OneStream, Inc.股票,OneStream, Inc.股票老虎,OneStream, Inc.股票老虎国际,OneStream, Inc.行情,OneStream, Inc.股票行情,OneStream, Inc.股价,OneStream, Inc.股市,OneStream, Inc.股票价格,OneStream, Inc.股票交易,OneStream, Inc.股票购买,OneStream, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"OneStream, Inc.(OS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest OneStream, Inc.(OS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction